SEC Filings |
|||
| Filing Date | Form | Description | |
| October 06, 2021 | 6-K | Biophytis S.A. issued a press release announcing it will host a virtual key opinion leader (KOL) event on October 6th, 2021, on its lead projects, Sarconeos (BIO101) for the treatment of COVID-19 and Sarcopenia | 
|
| October 05, 2021 | 6-K | On October 4, 2021, Biophytis S.A. issued a press release announcing the drawing of 2 new tranches of ORNANE under the 2020 Atlas contract for € 6 million |
|
| October 04, 2021 | 6-K | Biophytis announces promising full results from the SARA-INT Phase 2b trial of Sarconeos (BIO101) in Sarcopenia at the 11th annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 – October 2, 2021 |
|
| September 30, 2021 | 6-K | Biophytis to Present Full Results from the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29–October 2, 2021 |
|
| September 17, 2021 | 6-K | Biophytis reports H1 2021 financial results and provides business update |
|
| September 15, 2021 | 6-K | Biophytis announces DMC second interim analysis efficacy results in the promising zone allowing continuation of phase 2/3 COVA study with Sarconeos (BIO101) in COVID-19 |
|
| June 30, 2021 | 6-K | Biophytis announces that the results of SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be released by August 2021 |
|
| June 30, 2021 | 6-K | Biophytis announces that it will secure the manufacturing of Sarconeos (BIO101) for COVID-19 with a global CDMO and the next milestones for the COVA Phase 2-3 study |
|
| June 18, 2021 | 6-K | Biophytis announces new convertible bonds financing upt to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 million |
|
| May 12, 2021 | 6-K | Biophytis Completed the Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis |
|
| May 11, 2021 | 6-K | Results of the Combined General Meeting on May 10, 2021 |
|
| April 30, 2021 | 6-K | Biophytis Second Combined General Meeting to take place on May 10, 2021 without the physical presence of its shareholers |
|
| April 29, 2021 | 6-K | Biophytis Receives €980,000 DeepTech Funding from BPI France for the Development of Macuneos (BIO201) in Dry AMD |
|
| April 27, 2021 | 6-K | Convening of another Combined General Meeting at a later date |
|
| April 26, 2021 | 6-K | Biophytis gives operational perspectives on its Sarconeos (BIO101) ahead of its upcoming AGM on April 26, 2021 |
|
| March 22, 2021 | 6-K | Biophytis gives update on its Phase 2-3 COVA study on COVID-19 |
|
| March 19, 2021 | 6-K | Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis against Negma Group Ltd |
|
| March 12, 2021 | 6-K | Annual General Meeting will take place on April 26, 2021 |
|
| March 11, 2021 | 20-F | Annual Report for the Fiscal Year Ended Dec 31, 2020 |
|
| Feb 26, 2021 | 6-K | Biophytis Reports 2020 Full Year Results |
|
| Feb 17, 2021 | 6-K | Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial |
|
| Feb 16, 2021 | 6-K | Report of Foreign Private Issuer |
|
| Feb 9, 2021 | Final Prospectus |
|
|
| Feb 9, 2021 | F-1 | Amendment No 3 |
|
| Feb 8, 2021 | FWP | Free Writing Prospectus |
|
| Feb 4, 2021 | F-8A | For Registration of Certain Classes of Securities Pursuant to Section 12(b) or (g) |
|
| Feb 4, 2021 | F-1 | Amendment No 2 |
|
| Feb 2, 2021 | FWP | Free Writing Prospectus |
|
| Feb 2, 2021 | F-1 | Amendment No 1 |
|
| Jan 19, 2021 | F-1 | Form F-1 |
|
| Dec 23, 2020 | F-1 | Draft Registration Statement |
|
| Nov 20, 2020 | F-1 | Draft Registration Statement |
|
Biophytis
LIVE HEALTHIER LONGER
